Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224067 · ClinicalTrials.gov registry record · Phase 4
Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults
A Phase 4 study of Social Anxiety Disorder, sponsored by Cambridge Health Alliance.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01224067 is a Phase 4 study of Social Anxiety Disorder that has completed, run by Cambridge Health Alliance. The registered enrollment target is 40 participants, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01224067, a Phase 4 study of Social Anxiety Disorder, has completed, sponsored by Cambridge Health Alliance.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 16-week research study in which participants suffering from Social Anxiety Disorder (SAD) will receive Sertraline (a medication FDA approved for the treatment of SAD) for the first 8 weeks. If a participant remains symptomatic, he/she will enter the second phase of the study in which he/she continues taking Sertraline but also randomly receives either Seroquel or placebo in conjunction with Sertraline for additional 8 weeks. The purpose of this study is to determine the efficacy of adjunctive Seroquel in treating SAD.
Conditions Studied
Interventions
- DRUG Quetiapine
Study Locations (1)
Massachusetts
- Cambridge Health Alliance - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01224067
The ClinicalTrials.gov registry entry for NCT01224067 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (75% lower). The listed sponsor is Cambridge Health Alliance, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention - of which Quetiapine is the first listed.
NCT01224067 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01224067 about?
NCT01224067 is a clinical study titled "Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults". This is a 16-week research study in which participants suffering from Social Anxiety Disorder (SAD) will receive Sertraline (a medication FDA approved for the treatment of SAD) for the first 8 weeks. If a participant remains symptomatic, he/she will enter the second phase of the study in which he/sh...
What is the current status of trial NCT01224067?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-03. Estimated completion is 2008-10.
What conditions does trial NCT01224067 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT01224067?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT01224067?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01224067 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder
COMPLETED · Phase 4
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
RECRUITING · Phase 2
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.